Vimarsana
Biggest News Aggregation in the World

Page 2 - Pharma Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pharma Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pharma Ltd Today - Breaking & Trending Today

Indices: Stock market update: Nifty Pharma index advances 0.6% in an upbeat market - Vimarsana News

Indices: Stock market update: Nifty Pharma index advances 0.6% in an upbeat market

The Nifty Pharma index was trading 0.6 per cent up at 18974.0.

Gland Pharma gets USFDA nod for generic Edaravone injection - Vimarsana News

Gland Pharma gets USFDA nod for generic Edaravone injection

The approval by the US Food and Drug Administration (USFDA) is for Edaravone injection of strengths 30 mg/100 ml and 60 mg/100 ml single-dose bags, Gland Pharma said in a regulatory filing.

IM Cannabis : MONTHLY PROGRESS REPORT - Form 6-K - Vimarsana News

IM Cannabis : MONTHLY PROGRESS REPORT - Form 6-K

MONTHLY PROGRESS REPORT Name of Listed Issuer: IM Cannabis Corp. Trading Symbol: IMCC Number of Outstanding Listed...

MPs Oppose Allocation of Shs 578 billion to Dei BioPharma Ltd, Speaker Calls for valuation - Vimarsana News

MPs Oppose Allocation of Shs 578 billion to Dei BioPharma Ltd, Speaker Calls for valuation

Parliament has approved a supplementary expenditure budget worth Shs1.106 trillion for settling the offtake arrangement between government and DEI Pharmaceuticals, wage and pension and gratuity shortfalls. During plenary on Tuesday, 30 April 2023, the Deputy Chairperson of the Budget Committee, Remigio Achia, presented the committee's report approving the supplementary. Achia said the government has initiated

The Case for Using Filing Dates Instead of Expiration Dates to Determine Obviousness-Type Double Patenting (Part I) - Vimarsana News

The Case for Using Filing Dates Instead of Expiration Dates to Determine Obviousness-Type Double Patenting (Part I)

The judicially-created doctrine of obviousness-type double patenting (ODP) originated long ago as a shield to protect the public against unwarranted patent term extension (PTE).